Immutep Limited IMMP
Immutep Limited (Nasdaq: IMMP) is an oncology drug developer. Its lead program, eftilagimod alfa (efti, IMP321), is in Phase 2 for head and neck squamous cell carcinoma (HNSCC), 1st line, PD-L1 CPS <1.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| eftilagimod alfa (efti, IMP321) | non-small cell lung cancer (NSCLC), 1st line | protein/peptide | Phase 3 |
| eftilagimod alfa (efti, IMP321) | head and neck squamous cell carcinoma (HNSCC), 1st line, PD-L1 CPS <1 | protein/peptide | Phase 2 |
| eftilagimod alfa (efti, IMP321) | metastatic breast cancer (MBC) | protein/peptide | Phase 2 |
| eftilagimod alfa (efti, IMP321) | soft tissue sarcoma (neoadjuvant) | protein/peptide | Phase 2 |
| IMP701 (LAG525, ieramilimab) | not specified | antibody | Phase 1 |
| IMP761 | autoimmune disease | antibody | Pre-clinical |
| IMP731 | not specified | biologic-other | Pre-clinical |
Recent results and decisions
- Jul 30, 2026missed TACTI-004 Phase 3 was discontinued after a planned interim futility analysis; at interim (N=173) ORR was 42.9% for efti vs 55.1% for control, with no superiority in any PD-L1 subgroup.
In the interim futility analysis (N=173), the objective response rate was 42.9% in the efti arm compared with 55.1% in the control arm, with no superiority observed in any PD-L1 subgroup.
Filing - Jul 30, 2026positive Mature OS from single-arm INSIGHT-003 showed median OS of 30.9 months in the overall population (N=51), reported after quarter end.
Median OS was 30.9 months in the overall population (N=51) and in patients with PD-L1 TPS <50% (N=47).
Filing - Jul 30, 2026met Investigator-initiated EFTISARC-NEO Phase 2 met its primary objective with significant immune activation; patients still followed for disease-free survival.
has met its primary objective, with patients showing strong immune system activation in line with efti’s mode of action
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.